David A. Siegel Caribou Biosciences, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRBU
# of Institutions
138Shares Held
54.4MCall Options Held
21.2KPut Options Held
96.4K-
Black Rock Inc. New York, NY6.95MShares$7.43 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.57MShares$4.89 Million0.0% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA3.88MShares$4.15 Million0.4% of portfolio
-
Morgan Stanley New York, NY2.75MShares$2.94 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY2.5MShares$2.67 Million0.0% of portfolio
About Caribou Biosciences, Inc.
- Ticker CRBU
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,840,800
- Market Cap $65.1M
- Description
- Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...